Table 1 Demographic and clinical characteristics of the participants aged ≥75 years in the cohortstudy
All (n = 827) | Non-statin group (n = 698) | Statin group (n = 129) | P valuea | |
|---|---|---|---|---|
Clinical parameters | ||||
Female (n [%]) | 465 (56.2) | 392 (56.2) | 73 (56.6) | 0.928 |
Age (years) | 78.08 ± 2.38 | 78.00 ± 2.38 | 78.50 ± 2.39 | 0.028 |
Current smoking (n [%]) | 257 (31.1) | 218 (31.2) | 39 (30.2) | 0.822 |
Alcohol consumption (n [%]) | 271 (32.8) | 232 (33.2) | 39 (30.2) | 0.504 |
Hypertension (n [%]) | 554 (67.0) | 472 (67.6) | 82 (63.6) | 0.368 |
Antihypertensive medication (n [%]) | 425 (51.4) | 367 (52.6) | 58 (45.0) | 0.112 |
Diabetes (n [%]) | 98 (11.9) | 79 (11.3) | 19 (14.7) | 0.271 |
Lowering glucose medication (n [%]) | 91 (11.0) | 73 (10.5) | 18 (14.0) | 0.244 |
Dyslipidemia (n [%]) | 586 (70.9) | 490 (70.2) | 96 (74.4) | 0.333 |
Ischemic heart disease (n [%]) | 506 (61.2) | 422 (60.5) | 84 (65.1) | 0.319 |
Peripheral artery disease (n [%]) | 114 (13.8) | 93 (13.3) | 21 (16.3) | 0.371 |
Need statins for primary prevention (n [%]) | 720 (87.1) | 591 (84.7) | 129 (100.0) | – |
Statins (n [%]) | 129 (15.6) | 0 (0.0) | 129 (100.0) | – |
Simvastatin | 46 (5.6) | 0 (0.0) | 46 (35.7) | – |
Atorvastatin | 16 (1.9) | 0 (0.0) | 16 (12.4) | – |
Lovastatin | 7 (0.8) | 0 (0.0) | 7 (5.4) | – |
Fluvastatin | 11 (1.3) | 0 (0.0) | 11 (8.5) | – |
Pravastatin | 13 (1.6) | 0 (0.0) | 13 (10.1) | – |
Rosuvastatin | 36 (4.4) | 0 (0.0) | 36 (27.9) | – |
Antiplatelet medication (n [%]) | 187 (22.6) | 155 (22.2) | 32 (24.8) | 0.517 |
Body mass index (kg/m2) | 24.38 ± 2.53 | 24.36 ± 2.55 | 24.52 ± 2.39 | 0.506 |
Heart rate (bpm) | 70.67 ± 8.64 | 70.71 ± 8.73 | 70.48 ± 8.12 | 0.783 |
SBP (mm Hg) | 147.92 ± 16.69 | 148.20 ± 16.52 | 146.36 ± 17.58 | 0.250 |
DBP (mm Hg) | 75.82 ± 8.29 | 75.93 ± 8.24 | 75.21 ± 8.59 | 0.366 |
Biochemical parameters | ||||
TCHO (mmol/L) | 4.68 ± 0.75 | 4.72 ± 0.76 | 4.49 ± 0.68 | 0.001 |
TG (mmol/L) | 1.53 ± 0.49 | 1.56 ± 0.51 | 1.37 ± 0.30 | < 0.001 |
HDL-C (mmol/L) | 1.16 ± 0.35 | 1.15 ± 0.35 | 1.25 ± 0.35 | 0.002 |
LDL-C (mmol/L) | 2.82 ± 0.68 | 2.86 ± 0.68 | 2.62 ± 0.63 | < 0.001 |
FPG (mmol/L) | 5.42 ± 1.31 | 5.44 ± 1.32 | 5.30 ± 1.22 | 0.260 |
Brain magnetic resonance imaging | ||||
WMH (mL) | 5.02 (3.53, 6.37) | 5.18 (3.73, 6.51) | 4.25 (2.82, 5.48) | < 0.001 |
WMH-to-ICV ratio (%) | 0.38 (0.27, 0.48) | 0.40 (0.29, 0.49) | 0.32 (0.22, 0.40) | < 0.001 |
Prevalence of Fazekas scale ≥2 (n [%]) | 114 (13.8) | 104 (14.9) | 10 (7.8) | 0.031 |
Prevalence of lacunes (n [%]) | 98 (11.9) | 90 (12.9) | 8 (6.2) | 0.031 |
Prevalence of Virchow-Robin spaces (n [%]) | 140 (16.9) | 126 (18.1) | 14 (10.9) | 0.045 |
Prevalence of microbleeds (n [%]) | 67 (8.1) | 56 (8.0) | 11 (8.5) | 0.847 |